Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.48 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | PDXK | O00764 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8967900 | 0.94 | HPGD (0.61) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL140749 | 0.89 | HPGD (0.61) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL29040292 | 0.87 | HPGD (0.59) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL31536462 | 0.86 | HPGD (0.55) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL2133601 | 0.84 | HPGD (0.55) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL4612067 | 0.83 | HPGD (0.58) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Zinc Ion SCHEMBL31278847 | 0.82 | HPGD (0.52) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL29004449 | 0.81 | KDM4E (0.83) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL43879 | 0.81 | KDM4E (0.83) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL22857703 | 0.80 | HPGD (0.56) | HPGDKDM4EALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225378-A1 | REACTIVE CONJUGATES | Debiopharm Research & Manufacturing S.A. (CH) | 2023-08-16 | — | — | EP | claimed |
| US-20230046947-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-02-16 | — | — | US | claimed |
| EP-4069311-A1 | REACTIVE CONJUGATES | Debiopharm Research & Manufacturing SA (CH) | 2022-10-12 | — | — | EP | claimed |
| WO-2022078566-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | claimed |
| WO-2022079031-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | claimed |
| WO-2021110860-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2021-06-10 | — | — | WO | claimed |
| WO-2006028380-A1 | MRI METHOD FOR IMAGING OF THE HEART | KRANE JOSTEIN (NO) | 2006-03-16 | — | — | WO | claimed |
| US-20250345469-A1 | COMPOSITION COMPRISING A RAPALOG AND A RADIOLABELLED GASTRIN ANALOGUE, IN PARTICULAR FOR USE IN THE TREATMENT AND/OR DIAGNOSIS OF CCKB RECEPTOR POSITIVE CANCER OR TUMORS | SCHERRER INST PAUL (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20250170097-A1 | CATHEPSIN INHIBITORS AND USE THEREOF IN A METHOD FOR DETECTING AND TREATING RESISTANCE TO IMMUNOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-05-29 | — | — | US | disclosed |
| EP-4558175-A1 | CATHEPSIN INHIBITORS AND USE THEREOF IN A METHOD FOR DETECTING AND TREATING RESISTANCE TO IMMUNOTHERAPY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-05-28 | — | — | EP | disclosed |
| US-20250127940-A1 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. | 2025-04-24 | — | — | US | disclosed |
| US-20240401145-A1 | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT DIAGNOSED WITH CANCER TO TREATMENT AND/OR IMAGING WITH A COMPOUND TARGETING CCK2-R, AND COMPOUND FOR USE IN METHODS OF SELECTIVELY TREATING AND/OR IMAGING CANCER | PAUL SCHERRER INSTITUT (CH) | 2024-12-05 | — | — | US | disclosed |
| US-20240368223-A1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE | KAGOSHIMA UNIVERSITY (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2011003818-A2 | DIAGNOSTIC METHOD | CMC CONTRAST AB (SE) | 2011-01-13 | — | — | WO | disclosed |
| EP-2265207-A2 | SYSTEM AND METHOD FOR INDIRECTLY MEASURING CALCIUM ION EFFLUX | Celtrast LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010099804-A1 | MAGNETIC RESONANCE IMAGING OF THE LIVER | CMC CONTRAST AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010093635-A2 | SYSTEMS AND METHODS FOR MEASURING AND MODELING IN VIVO MANGANESE ION TRANSPORT IN A SUBJECT | CELTRAST LLC (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009123927-A2 | SYSTEM AND METHOD FOR INDIRECTLY MEASURING CALCIUM ION EFFLUX | CELTRAST LLC (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090246144-A1 | SYSTEM AND METHOD FOR INDIRECTLY MEASURING CALCIUM ION EFFLUX | CELTRAST LLC (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2006028380-A1 | MRI METHOD FOR IMAGING OF THE HEART | KRANE JOSTEIN (NO) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170097-A1 | CATHEPSIN INHIBITORS AND USE THEREOF IN A METHOD FOR DETECTING AND TREATING RESISTANCE TO IMMUNOTHERAPY | CTSZ, CTSV, CTSE | HPGD 2366/4885KDM4E 3020/4885ALDH1A1 2777/4885 |
| US-20230046947-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | HPGD 4053/4885KDM4E 3315/4885ALDH1A1 590/4885 |
| US-20240368223-A1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE | FCGR3B, NGLY1, FCGR2A | HPGD 2920/4885KDM4E 4189/4885ALDH1A1 4807/4885 |
| US-20250345469-A1 | COMPOSITION COMPRISING A RAPALOG AND A RADIOLABELLED GASTRIN ANALOGUE, IN PARTICULAR FOR USE IN THE TREATMENT AND/OR DIAGNOSIS OF CCKB RECEPTOR POSITIVE CANCER OR TUMORS | CCKBR, GRPR, CCKAR | HPGD 2452/4885KDM4E 4502/4885ALDH1A1 4858/4885 |
| US-20250127940-A1 | RADIOPHARMACEUTICAL AND METHODS | GALC, GCG, GUSB | HPGD 401/4885KDM4E 2225/4885ALDH1A1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.